公开(公告)号：EP2254878A1

公开(公告)日：2010-12-01

申请号：EP08713963.0

申请日：2008-01-24

申请人： Gilead Palo Alto, Inc. ,  The Endowment for Research in Human Biology, Inc.

发明人： BILOKIN, Yaroslav ,  ELZEIN, Elfatih ,  ZABLOCKI, Jeff ,  ORGAN, Michael ,  PERRY, Thao ,  KOBAYASHI, Tetsuya ,  ABELMAN, Matthew ,  KALLA, Rao ,  FAN, Peidong ,  DIAMOND, Ivan ,  JIANG, Robert ,  AROLFO, Maria, Pia ,  LI, Xiaofen ,  YAO, Lina ,  JIANG, Zhan ,  KEUNG, Wing Ming ,  TAO, Guoxin

IPC分类号： C07D311/36 ,  C07D405/04 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  A61K31/353 ,  A61P25/32

CPC分类号： C07D311/36 ,  C07D405/04 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

摘要： Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

公开(公告)号：EP1444233B1

公开(公告)日：2011-08-17

申请号：EP02793897.6

申请日：2002-11-08

申请人： Gilead Palo Alto, Inc.

发明人： KALLA, Rao ,  PERRY, Thao ,  ELZEIN, Elfatih ,  VARKHEDKAR, Vaibhav ,  LI, Xiaofen ,  IBRAHIM, Prabha ,  PALLE, Venkata, D-011, Oakwood Estates ,  XIAO, Dengming ,  ZABLOCKI, Jeff

IPC分类号： C07D473/00 ,  C07D473/06 ,  C07D473/08 ,  A61K31/52 ,  A61P1/12 ,  A61P11/06 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00

CPC分类号： C07D473/00 ,  C07D473/06 ,  C07D473/08

摘要： Disclosed are novel compounds of the Formula I or Formula II that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

公开(公告)号：EP2464645A1

公开(公告)日：2012-06-20

申请号：EP10737724.4

申请日：2010-07-26

申请人： Gilead Palo Alto, Inc.

发明人： CORKEY, Britton ,  ELZEIN, Elfatih ,  JIANG, Robert ,  KALLA, Rao ,  KOBAYASHI, Tetsuya ,  KOLTUN, Dmitry ,  LI, Xiaofen ,  NOTTE, Gregory ,  PARKHILL, Eric ,  PERRY, Thao ,  ZABLOCKI, Jeff

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/5025 ,  A61P9/00

CPC分类号： C07D487/04 ,  C07D471/04

摘要： The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.